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Abstract
Epithelial to mesenchymal transition (EMT), and the cardiovascular equivalent, endothelial to mesenchymal transition (EndoMT), contribute to a range of chronic degenerative diseases and cancer metastasis. Chronic valvulopathies exhibit some features of EndoMT and activation of developmental signalling pathways, such as osteogenesis and chondrogenesis, expression of cell differentiation markers, basement membrane damage and endothelial transformation. The aim of the present study was to investigate the potential role of developmental mechanisms in canine myxomatous mitral valve disease (MMVD), using a combination of transcriptomic array technology, RT-PCR and immunohistochemistry.

	There was significant differential expression for genes typically associated with valvulogenesis and EndoMT, including markers of inflammation (IL6, IL18 and TLR4), basement membrane disarray (NID1, LAMA2 and CTSS), mesenchymal and endothelial cell differentiation (MYH11 and TAGLN) and EndoMT (ACTA2, SNAI1, CTNNB1, HAS2, CDH5, and NOTCH1), with fold changes from +15.35 (ACTA2) to -5.52 (LAMA2). These changes in gene expression were confirmed using RT-PCR, except for HAS2. In silico analysis identified important gene networks and canonical pathways in MMVD that have associations with development and organogenesis, including inflammation, valve morphogenesis and EMT, as well as components of the basement membrane and extra-cellular matrix. Immunohistochemistry identified changes in expression of hyaluronic acid synthase (Has2), Snai1, α-smooth muscle actin (α-SMA) and VE-cadherin (CDH5), and co-expression of Has2 with α-SMA. These research findings strongly suggest involvement of developmental signalling pathways and mechanisms, including EndoMT, in the pathogenesis of canine MMVD.
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Introduction 
Myxomatous mitral valve disease (MMVD) is the most common acquired heart disease affecting dogs (Buchanan, 1977; Borgarelli and Buchanan, 2012). At a structural and cellular level, there is loss of collagen, accumulation of glycosaminoglycans, proliferation of α-smooth muscle actin (α-SMA) and embryonic smooth muscle myosin (Smemb) positive cells adjacent to the valve endothelium, with detachment and loss of endothelial cells (Rabkin et al., 2001; Disatian et al., 2010; Hadian et al., 2010; Han et al., 2010). The histopathological appearance of the diseased valve stroma and some of the cellular changes present, including  the appearance of the myxoid stroma itself, increased numbers of α-SMA positive cells, basement membrane damage and changes in the endothelium, are reminiscent of processes involved in valvulogenesis (Black et al., 2005; Han et al., 2010; Hinton and Yutzey, 2011).

	Osteogenesis and chondrogenesis have been identified in aortic and mitral valves, suggesting that developmental signalling pathways can be activated in different chronic valvulopathies (Cheek et al., 2012; Orton et al., 2012; Garside et al., 2013). Osteogenic differentiation capacity has been demonstrated with clonally expanded sheep mitral valvular endothelial cells (VECs), suggesting that a population of multi-lineage progentior cells exist in the valve endothelium, with the potential for mesenchymal differentiation. These may form part of a sub-set of VECs that can replenish valvular interstitial cells (VICs) as a consequence of life-long cell loss and in response to disease (Bischoff and Aikawa 2011; Wyler-Sears et al, 2011). Endothelial-to-mesenchymal transition (EndoMT) has also been shown to be activated by inflammatory cytokines in adult porcine aortic VECs (Mahler et al., 2013).

EndoMT is involved in valvulogenesis and there are clear examples of a role for EndoMT and epithelial to mesenchymal transition (EMT), in a variety of diseases such as chronic fibrosis of the lung, kidney and heart and in cancer metastasis (Li and Bertram, 2010; Piera-Velazquez et al., 2011; Kovacic et al., 2012). EndoMT is closely regulated by a wide range of signalling pathways and transcription factors, including vascular endothelial growth factor (VEGF) (cell proliferation), NOTCH (induction of EndoMT) and Snail and Slug (VE-cadherin, α-SMA and fibronectin expression) (Armstrong and Bischoff, 2004; Butcher and Markwald, 2007; Hinton and Yutzey, 2011). The hallmark of EndoMT is loss of the VEC marker CD31 and cell-to-cell contact (assessed by CDH5 / VE-cadherin expression), and upregulation of α-SMA expression (Bischoff and Aikawa, 2011; Kovacic et al., 2012).

Members of the transforming growth factor (TGF)-β/bone morphogenic protein (BMP) superfamily also mediate cell differentiation, endothelial cell separation and degradation of the basal lamina, permitting migration of transformed endothelial cells (Boyer et al., 1999; Song et al., 2000; Butcher and Markwald, 2007). BMPs are important in valve development and their expression appears prior to the onset of EndoMT, triggering production of TGF-β, hyaluronic acid synthase 2 (Has2), NOTCH and the transcription factors Snail and Twist (Chen and Massagué, 1999; Ma et al., 2005). The appearance of hyaluronic acid allows invasion and further migration of cells into the cardiac jelly and promotes cell proliferation and differentiation by inducing expression of PI3 kinase and ErbB2/3 (Mjaatvedt et al., 1998; Garside et al., 2013). 

There is evidence of a role for EndoMT/EMT in a range of chronic diseases and some of the stromal and cellular changes seen in MMVD suggest a tissue type similar to that seen in embryonic development of the valve. Therefore, the aim of the present study was to examine the possibility of re-activation and recruitment of developmental processes in canine MMVD, based on analysis of transcriptomic data (Lu et al., 2015), further investigated by real time quantitative PCR and immunohistochemistry.

Materials and methods
Tissue samples
All tissue samples were collected with informed owner consent and the study conformed to national (UK) and institutional ethical guidelines for the use of animals and their tissues in research. For immunohistochemistry, myxomatous mitral valve leaflets (n = 14) were collected at necropsy from cavalier King Charles Spaniels (CKCS; n = 9) and mixed breed dogs (n = 5) presented to the Hospital for Small Animals, Royal (Dick) School of Veterinary Study, the University of Edinburgh. Control tissue from anterior mitral valve leaflets (n = 10) were collected from young adult dogs that had been euthanased for reasons other than cardiac disease. All samples were immediately fixed in 4% paraformaldehyde. Valves were assessed for the presence of gross lesions by two of the three investigators (CCL, BMC, GC) and classified according to an established scheme (Whitney, 1974). For transcriptomic analysis, valvular tissues from four CKCS and four control dogs had been assessed and the results reported by Lu et al., 2015.

RNA extraction
One hundred milligrams of tissue was minced, snap-frozen in liquid nitrogen and pulverised for 1 min at 2000 oscillations per min in a liquid nitrogen-cooled dismembranator (Mikro-Dismembrator Vessel, Braun Biotech International). One millilitre of TriReagent (Sigma–Aldrich) and 200 µL of chloroform were added, followed by centrifugation (12,000 g for 10 min). RNA extraction and contaminant genomic DNA digestion were carried out using commercially available kits (RNeasy Mini Kit and RNase-Free DNase Set, Qiagen). The RNA purity was analysed by spectrophotometry (NanoDrop 1000, Thermo Scientific; 260/280 absorbance ratio ~2) and RNA quality and RNA integrity number (RIN ≥7) determined by electropherogram (Agilent 2100 Bioanalyser). The RNA samples were stored at -80° C prior to further processing.

Microarray hybridization and analysis
The GeneChip WT Terminal Labelling Kit (Affymetrix), combined with WT Expression Kit (Ambion), were used to generate amplified and biotinylated sense-strand DNA targets for the Affymetrix Canine Gene 1.0 ST Array. The two cycle RNA-cDNA amplification, hybridization, and chip scanning were undertaken by ARK-Genomics (Roslin Institute).

For differential gene expression analysis, all the raw Affymetrix CEL files were imported into Partek Genomic Suite version 6.6 software (Partek). Robust Multi-array Average (RMA) was used for data normalisation and final summarisation, and Student’s t-test was used to identify differentially expressed genes comparing the two groups (cases and controls). Network pathway analysis, including biological functions identification, was undertaken using the Ingenuity Pathways Analysis (IPA) database.​[1]​ Normalised signal intensity data for whole probe sets were also produced by Affymetrix Expression Console.

Real time quantitative PCR
Six RNA samples (3 CKCS affected with MMVD and 3 controls), that had been analysed my microarray, were assessed by quantitative real-time PCR. Assays were designed for four candidate genes (determined by signal intensity), six differentially expressed genes, and one reference gene (MRPS25) that had previously been validated for normalising real-time quantitative PCR data generated from canine heart valve tissue (Yang et al., 2012) (see Appendix: Supplementary Table S1). Primers (MWG Biotech) and labelled probes (Roche Diagnostics) were synthesised and real-time quantitative PCR assays were performed in triplicate in 96 well plates (LightCycler 480; Roche Diagnostics) with one no-template control for each sample. Reaction volumes consisted of 5 μL LightCycler 480 Probes Master (Roche Diagnostics) (See Appendix: Supplementary Table S1 and Supplementary File 1). Real-time quantitative PCR data were analysed using LightCycler 480 Basic Software (Roche Diagnostics). The reference gene (MRPS25) was used to normalise the relative expression of the target genes, using the comparative Ct (∆∆Ct method) (Yang et al., 2012).

Immunohistochemistry and immunofluorescence
Primary antibodies were against α-SMA (Sigma-Aldrich), vascular endothelial (VE)-cadherin (CDH5) (Abcam), Snail (Santa Cruz Biotechnology), and hyaluronic acid synthase 2 (Has2) (Abcam) (see Appendix: Supplementary Table S2). Immunoreactivity was visualised either using a standard peroxidase method for immunohistochemistry, with NovaRed as the chromagen (ABC Elite Kit, Vector Laboratories) or using either AlexaFluor488 or AlexaFluor568 conjugated secondary antibodies (Invitrogen) for immunofluorescence.

For paraformaldehyde-fixed tissues (n = 14 MMVD cases and n = 10 controls) antigen retrieval was undertaken by heating in citrate buffer (0.01 M, pH 6.0) for 5 min at 120 °C using a HISTO5 Rapid Microwave Histoprocessor (Milestone). For the peroxidase technique, sections were incubated with 1% hydrogen peroxide in phosphate-buffered saline (PBS, pH 7.4) for 10 min and blocked with 10% goat serum diluted in PBS supplemented with 0.5% Tween 20 (PBST, Vector Laboratories) for 30 min at room temperature. Sections were then incubated for 60 min at room temperature with the primary antibodies, rinsed in PBST, incubated for 30 min at room temperature with the biotinylated secondary antibody (goat anti-rabbit IgG, Vector Laboratories), counterstained with haematoxylin, dehydrated through graded ethanols and xylene and mounted in a xylene-based medium (DePex, Gurr-BDH Chemicals). For immunofluorescence, the protocol was similar but without addition of hydrogen peroxide, and the secondary antibody was applied for 60 min at room temperature in a dark humid chamber. Slides were washed in PBS (three times for 5 min each), mounted and nuclei counterstained with DAPI (Prolong Gold, Life Technologies). 

Image capture and statistical analysis
Images were captured using light microscopy with fluorescent filters (Leica-DMLB). Semi-quantitative analysis of staining was graded as: 0, no staining; 1, mild (<29% of cells); 2, marked (30–59% of cells); 3, diffuse and strong (>60% of cells). Qualitative and semi-quantitative assessment was carried out on the NovaRed stained sections (Has2). Fluorescent double-labelled sections (α-SMA/CDH5, α-SMA/Has2, and α-SMA/Snai1) were examined qualitatively. 

Results 
Validation of microarray data with quantitative PCR
The results of microarray analysis, previously undertaken with these samples (Lu et al., 2015) was confirmed by real-time quantitative PCR assays for ACTA2, CDH5, NOTCH1, SNAI1, and HAS2 (Fig. 1). There was good agreement between the microarray findings (signal intensity) and statistically significant differences between normal and disease groups, with the exception of HAS2.

Transcriptional profiling identifies a potential role for EndoMT in MMVD
In silico analysis of microarray data identified networks, mainly associated with inflammation and maintanance of basement membrane integrity (Table 1). Expression of the genes IL6, IL18 and TLR4 were significantly upregulated. Basement membrane disruption was suggested by down-regulation of genes associated with basement membrane components (NID1, LAMA2) and increased expression of the basement membrane cleavage enzyme, cathepsin S (CTSS). The differentially expressed genes also included myofibroblastic differentiation transcripts such as MYH11 and TAGLN. Furthermore, normalised signal intensity for each probe set revealed greater mRNA expression of genes implicated in EndoMT including, ACTA2, SNAI1, CTNNB1, and HAS2, whereas there was lowered expression of CDH5, which favours endothelial cell migration. There was differential expression of NOTCH signalling transcripts, including NOTCH1, RBPJ, NFATc1 and NFATc2. 

Increase in HAS2 expression in myxomatous mitral valves
In normal mitral valves, immunoreactivity for Has2 was observed in endothelial cells, predominantly in the atrialis, and along the whole leaflet length, with sparse expression in the spongiosa (Fig. 2A). In the myxomatous mitral valve distal zone, Has2 expression was diffuse and significantly greater than in normal valves (P <0.001; Fig. 2B). Staining was also found in the mid-zone of MMVD valves, but was not significantly different to that seen in normal valves (Fig. 2). Co-expression of Has2 and α-SMA was identified in small numbers of myofibroblasts in MMVD and in endothelial cells in those regions where there was no sub-endothelial myofibroblast accumulation (Fig. 3).

Snai1 expression in myofibroblast clusters in myxomatous mitral valves
In normal mitral valves, expression of Snail was minimal, and was localised to the endothelium (Fig. 4A). In myxomatous mitral valves, cells expressing Snai1 were identified in the cell dense layer at the tip of the leaflet and in the stroma of myxomatous areas (Fig. 4B–D). The cells were round in shape and distinctly different from the adjacent spindle-shaped α-SMA positive cells. Furthermore, the Snai1 positive cells found in myofibroblast clusters in the myxomatous mitral valves were predominantly α-SMA negative, with relatively few cells weakly co-expressing α-SMA.

VE-cadherin (CDH5) and α-SMA are co-expressed in normal and diseased mitral valves
VE-cadherin was clearly expressed in the endothelium of both normal (Fig. 5A) and myxomatous (Fig. 5B) mitral valves, with some of these cells co-expressing α-SMA (Fig. 5C). Low level expression of VE-cadherin was observed in interstitial cells in the spongiosa layer of normal mitral valves, which was more pronounced in myxomatous regions of diseased valves (Fig. 5). Individual α-SMA positive cells in normal mitral valves usually lay underneath and in close proximity to VE-cadherin expressing endothelial cells, whereas in myxomatous mitral valves, α-SMA positive cells aggregated in multiple layers.

Discussion
The results of this study provide evidence of developmental signalling pathways and EndoMT in canine MMVD, by examining gene expression of ACTA2 (α-SMA), CTNNB1 (β-cateninin), CDH5 (VE-cadherin), NOTCH1, SNAI1 and HAS2. Other genes identified by microarray analysis implicate other biological mechanisms in the pathogenesis of MMVD, including the inflammatory response, basement membrane disruption and mesenchymal differentiation. In heart valves from dogs affected with MMVD, there was increased expression of these genes, with the exception of NOTCH1, and a reduction in CDH5. Apart from down-regulation of NOTCH1 expression, all other changes support a potential contribution of EndoMT and endothelial migration in the pathogenesis of MMVD. 

Increased expression of Has2 in the myxoid stroma and close to the endothelium of diseased valves is reminiscent of the events that drive EndoMT in valvulogenesis (Camenisch et al., 2000; Bakkers et al., 2004; Lagendijk et al., 2013). Furthermore, co-expression of Has2 with α-SMA in some of the endothelial and interstitial cells implies mesenchymal cell differentiation is present in diseased valves (Klewer et al., 2006). While VE-cadherin is clearly expressed in both normal and diseased valve endothelium, suggesting cell-to-cell contact has not been lost, there was increased expression of Snai1 in the endothelium of MMVD valves and a reduction in CDH5 gene expression. Snai1 is the down-stream transcription factor of the Notch-TGF-β signalling pathway, important for EndoMT, and which controls expression of endothelial cell markers, thereby allowing EndoMT to occur (Barrallo-Gimeno and Nieto, 2005; Kokudo et al., 2008). Furthermore, in valvulogenesis, Snai1 increases expression of mesenchymal cell markers, such as α-SMA (Barrallo-Gimeno and Nieto, 2005). 

Studies of canine MMVD to date have examined cellular and molecular events, where there is end-stage disease present. Evidence has emerged from several studies, suggesting that myxomatous degeneration in the valve results from activation of a quiescent VIC population in the valve stroma to an activated myofibroblast phenotype, and that these cells then contribute to inappropriate remodelling of the valve (Liu et al., 2007). The trigger for this might be endothelial activation and/or damage, which then results in activation of the TGF-β/5-hydroxytryptamine signalling pathway, enabling transformation to a VIC phenotype (Ng et al., 2004; Aupperle et al., 2008; Aupperle and Disatian, 2012; Geirsson et al., 2012). EndoMT suggests an alternative pathway, whereby the α-SMA positive cells, seen in MMVD, are not exclusively a transformed VIC population, but derived from the valve endothelial cells.

Expression of Notch promotes non-invasive EndoMT in a Snail1 and TGF-β2–dependent manner, but for invasive EndoMT, BMP2 secretion from the adjacent myocardium is required, inducing EndoMT by maintaining Snai1/2 activity in conjunction with Notch (Rabkin et al., 2001; Garside et al., 2013). Surprisingly, Notch expression was greater in normal mitral valves, but downstream targets of Snai1, such as ACTA2, SM22 and CDH5 were still affected. These findings suggest there may be a NOTCH-independent Snai1 signalling pathway in MMVD, and normal NOTCH expression might play a crucial role in maintaining a healthy mitral valve. In normal canine mitral valves there was strong expression of Snai1, but only seen in the endothelial cells, which might represent routine endothelial repair mechanisms operating through EndoMT. In myxomatous mitral valves, Snail positive cells were found within the myofibroblast clusters at the leaflet surface and in the stroma. These Snail positive cells were mostly α-SMA negative and showed a distinct round shaped morphology, compared with the adjacent spindle-shaped myofibroblasts. These Snail positive/α-SMA negative cells might be trans-differentiated cells through partial EndoMT (acquiring a migratory phenotype, without expressing α-SMA) and originating from surface endothelial cells (Craig et al., 2010). 

Has2 is highly expressed during heart development and is involved in endocardial cushion expansion (Camenisch et al., 2000; Ng et al., 2004; Aupperle et al., 2010; MacGrogan et al., 2011). In the adult heart, hyaluronan is mainly found in aortic and mitral valve leaflets and appears to contribute to normal valve remodelling, but changes in hyaluronan synthesis have been noted in human myxomatous mitral valves suggesting a role in disease (Bakkers et al., 2004; Toole, 2004; Lagendijk et al., 2011). Hyaluronan can induce EndoMT, and increase cell migration through ErbB2 phosphorylation effects on β-catenin expression (Maroski et al., 2011; Rodriguez et al., 2011). In normal canine mitral valves, Has2 expression was mainly seen in the endothelium, at the atrial and ventricular sides. In the spongiosa of normal mitral valves, a few spindle-shape interstitial cells (α-SMA negative) expressed Has2, possibly identifying a pro-migratory phenotype of VICs (Camenisch et al., 2001; Ma et al., 2005; Bourguignon et al., 2007). 

Conclusions
Evidence of EndoMT and other developmental pathways was identified in normal and myxomatous mitral valves, with those valves from dogs affected with MMVD showing increased gene expression of ACTA2 (α-SMA), CDH5 (VE-cadherin), SNAI1 and HAS2, but down-regulation of CDH5. Co-expression of VE-cadherin and α-SMA in normal (endothelial cells) and myxomatous mitral valves (stroma cells) suggests that some myofibroblasts may originate via EndoMT. EndoMT suggests an additional contibuting factor to the disease pathogenesis, whereby the α-SMA positive cells seen in MMVD partially originate from the VIC population and partially by differentiation and migration of endothelial cells.
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Table 1.
Microarray analysis identified differentially expressed genes associated with inflammation, maintainance of basement membrane integrity and Notch signalling.

Category		Gene (symbol)	Fold-	P value	Signal intensity b
		change a		Control	MMVD
Inflammatory	Interleukin 6 (IL6)	7.86	0.0048	21	176
	Interleukin 18 (IL18)	6.92	0.0029	97	667
	Toll-like receptor 4 (TLR4)	2.34	0.0007	371	826
					
Basement 	Nidogen 1 (NID1)	-3.08	0.0004	1645	467
membrane	Laminin 2 (LAMA2)	-5.15	0.0011	365	69
	Cathepsin S (CTSS)	2.26	0.0001	1405	3310
					
Mesenchymal differentiation (myofibroblastic)	Myosin heavy chain 11 (MYH11)	4.93	0.005	80	438
	Transgelin (TAGLN)	2.39	0.0042	1635	3994
	Smooth muscle actin α (ACTA2)	10.66a	0.027	329	1857
	Smooth muscle actin γ (ACTG2)	15.35	0.0031	73	1473
	SNAI1	4.80a	0.045	162	419
	Vascular endothelial cadherin (CDH5)	-2.59a	0.029	1630	877
	Bone morphogenetic protein 6 (BMP6)	2.38	0.0006	293	755
	β-catenin (CTNNB1)	1.38	0.0037	1866	2642
	Hyaluronic acid synthase 2, (HAS2)	2.18	0.0001	417	934
					
Notch signalling	NOTCH1	-2.33	0.0001	545	247
	RBPJ	1.60	0.0034	1401	2312
	NFATc1	-1.87	0.0036	908	517
	NFATc2	-2.13	0.0066	329	159

a Fold-change determined by real time quantitative PCR.
b Signal intensity represents the raw microarray data.


Figure legends

Fig. 1. Real time quantitative PCR analysis of candidate genes. (A) Relative gene expression of ACTA2, CDH5, NOTCH1, SNAI1, and HAS2 was determined by real-time quantitative PCR using the comparative ∆∆Ct method. (B) Signal intensity of ACTA2, NOTCH1, CDH5, SNAI1 and HAS2 for myxomatous and normal mitral valves. Bars represent mean  SD of n = 6 samples. *P <0.05, ***P <0.001, NS, not significant.

Fig. 2. Representative immunostaining for Has2. (A) In the mid-zone of normal mitral valves, Has2 was expressed by interstitial cells in the spongiosa and endothelial cells at the atrial and ventricular surface, with a minimal amount expressed in the fibrosa layer. In the mid-zone of valves affected by myxomatous degeneration, Has2 expression was similar to the normal mitral valve. In the distal region of normal valves, Has2 was expressed by endothelial cells at the valve surface and a few interstitial cells, whereas in a similar area of myxomatous valves Has2 was strongly expressed by most interstitial cells. Hematoxylin counterstain. Scale bar = 50 µm. (B) Semi-quantitative analysis showed Has2 expression to be significantly greater in the distal portion of the myxomatous mitral valves compared with normal valves. There was no difference in Has2 expression in the mid-zone of the myxomatous and normal mitral valves. Mean  SD; Grade = staining 0 (none) to 3 (diffuse, strong >60% cells); NS, not significant; **P < 0.001.

Fig. 3. Photomicrographs of immunofluorescence staining for α-SMA (green; upper panels) and Has2 (red; middle panels). Merged images are shown in lower panels; DAPI nuclear counterstaining (blue). (A) Atrial endothelial cells of a normal mitral valve co-expressing Has2 and α-SMA (arrows). Scale bar = 25 µm (B) Atrial endothelial cells of a normal mitral valve positive for Has2 or α-SMA but with no evidence of co-expression. Scale bar = 25 µm (C) Co-expression (arrow) of Has2 and α-SMA in a small number of cells in the myofibroblast clusters in the distal zone of a myxomatous mitral valve. Scale bar = 50 µm. (D) Co-expression of Has2 and α-SMA in an elongated and spindle-shaped cell (arrow), near the mitral valve surface of a myxomatous mitral valve. Scale bar = 25 µm. 

Fig. 4. Photomicrographs of immunofluorescence staining for α-SMA (green; upper panels), and Snai1 (red; middle panel). Merged images are shown in lower panels; DAPI nuclear counterstaining (blue). (A) Snai1 is expressed by relatively few endothelial cells and α-SMA by occasional cells (faint staining) in the valve stroma (arrow) of a normal mitral valve, but no evidence of co-expression. Scale bar = 50 µm. (B) Spindle shaped α-SMA positive myofibroblasts and more round Snai1 positive cells in the stroma of a myxomatous valve, with only occasional cells showing co-expression (arrow). Scale bar = 25 µm. (C and D) Myofibroblast clusters close to the endothelium with Snai1 positive cells mainly distributed along the endothelium and a few Snai1 positive cells in the stroma. There are occasional cells showing co-expression in the endothelium (arrow). Scale bar = 25 µm. 

Fig. 5. Photomicrographs of immunoreactivity for VE-cadherin (CDH5). (A) Immunohistochemistry for VE-cadherin in a normal mitral valve showing endothelial cells positively stained with occasional weakly positive cells in the stroma. Scale bar = 25 µm. (B) Immunohistochemistry for VE-cadherin in a myxomatous mitral valve showing endothelial and several stromal interstitial cells positively stained. Scale bar = 25 µm. (C) Immunofluorescence staining for VE-cadherin (red; upper panel) and α-SMA (green; middle panel). Merged image shown in lower panel; DAPI nuclear counterstaining (blue). VE-cadherin and α-SMA positive endothelial cells were observed on the atrial side, with evidence of co-expression (arrows and insert lower panel). Scale bar = 25 µm.

Figure 1

Figure 2

Figure 3

Figure 4


Figure 5













^1	  See: http://www.ingenuity.com/products/ipa 
